WO2002102345A3 - Deferoxamine as an no synthase inhibitor and uses thereof - Google Patents

Deferoxamine as an no synthase inhibitor and uses thereof Download PDF

Info

Publication number
WO2002102345A3
WO2002102345A3 PCT/FR2002/002065 FR0202065W WO02102345A3 WO 2002102345 A3 WO2002102345 A3 WO 2002102345A3 FR 0202065 W FR0202065 W FR 0202065W WO 02102345 A3 WO02102345 A3 WO 02102345A3
Authority
WO
WIPO (PCT)
Prior art keywords
deferoxamine
synthase inhibitor
composition
desferal
synthase
Prior art date
Application number
PCT/FR2002/002065
Other languages
French (fr)
Other versions
WO2002102345A2 (en
Inventor
Marie-Madeleine Cals-Grierson
Original Assignee
Oreal
Marie-Madeleine Cals-Grierson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal, Marie-Madeleine Cals-Grierson filed Critical Oreal
Publication of WO2002102345A2 publication Critical patent/WO2002102345A2/en
Publication of WO2002102345A3 publication Critical patent/WO2002102345A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Abstract

The invention relates to the use of an effective quantity of deferoxamine (desferal) in a physiologically acceptable medium, in a composition or in the preparation of a composition, the desferal or composition being used to inhibit NO synthase.
PCT/FR2002/002065 2001-06-15 2002-06-14 Deferoxamine as an no synthase inhibitor and uses thereof WO2002102345A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107876A FR2825920B1 (en) 2001-06-15 2001-06-15 DESFERAL AS INHIBITOR OF NO-SYNTHASE AND USES
FR01/07876 2001-06-15

Publications (2)

Publication Number Publication Date
WO2002102345A2 WO2002102345A2 (en) 2002-12-27
WO2002102345A3 true WO2002102345A3 (en) 2003-03-20

Family

ID=8864372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/002065 WO2002102345A2 (en) 2001-06-15 2002-06-14 Deferoxamine as an no synthase inhibitor and uses thereof

Country Status (2)

Country Link
FR (1) FR2825920B1 (en)
WO (1) WO2002102345A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
FR2940615B1 (en) 2008-12-30 2011-12-30 Oreal ASSOCIATION OF MONOSACCHARIDES WITH ANTIOXIDANT AGENTS AND ITS USE IN COSMETICS
EP2467135B1 (en) 2009-08-19 2017-02-01 Mordechai Chevion Desferrioxamine-metal complexes for the treatment of immune-related disorders
JP7118591B2 (en) 2017-02-28 2022-08-16 ロレアル Compositions containing resorcinol or derivatives thereof
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for fat graft retention
CA3113175A1 (en) * 2018-09-20 2020-03-26 Tautona Group Ip Holding Company, L.L.C. Iron chelating compounds for treating aesthetic skin conditions
JP7412898B2 (en) 2019-04-26 2024-01-15 ロレアル Combination of unique particles and lipophilic antioxidants
JP2021095354A (en) 2019-12-16 2021-06-24 ロレアル Stable composition containing combination of specific components
WO2023120390A1 (en) 2021-12-20 2023-06-29 L'oreal Stable composition comprising retinoid and ascorbic acid compound
FR3131837A1 (en) 2022-01-19 2023-07-21 L'oreal STABLE COMPOSITION COMPRISING A RETINOID AND AN ASCORBIC ACID COMPOUND
WO2023120259A1 (en) 2021-12-20 2023-06-29 Oreal Stable composition comprising retinoid
FR3131845A1 (en) 2022-01-19 2023-07-21 L'oreal STABLE COMPOSITION COMPRISING RETINOID

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (en) * 1966-03-04 1969-09-29
EP0313305A2 (en) * 1987-10-22 1989-04-26 The Procter & Gamble Company Photoprotection compositions comprising chelating agents
EP0535446A1 (en) * 1991-09-30 1993-04-07 BONISCONTRO E GAZZONE S.r.l. Pharmaceutical compositions for topical use containing a chelating agent, a tocopheral and an antimicrobial agent
WO1994026263A2 (en) * 1993-05-06 1994-11-24 The Wellcome Foundation Limited Use of a transition metal complex for the treatment of septic shock
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
JPH08333260A (en) * 1995-06-06 1996-12-17 Kaminomoto Honpo:Kk Skin preparation for external use
WO1997015280A1 (en) * 1995-10-26 1997-05-01 L'oreal Use of at least one no synthase inhibitor for treating sensitive skin
US5683684A (en) * 1991-04-03 1997-11-04 L'oreal Use of sphingolipids in the preparation of a cosmetic or dermopharmaceutical composition protecting the skin and hair against the harmful effects of atmospheric pollution
JPH10120557A (en) * 1996-10-16 1998-05-12 Sekisui Chem Co Ltd Substance for treating wound
JPH10279485A (en) * 1997-04-01 1998-10-20 Nisshin Oil Mills Ltd:The Composition
US6150405A (en) * 1985-07-18 2000-11-21 Proctor; Peter H. Hair loss treatment with ascorbates

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7302M (en) * 1966-03-04 1969-09-29
US6150405A (en) * 1985-07-18 2000-11-21 Proctor; Peter H. Hair loss treatment with ascorbates
EP0313305A2 (en) * 1987-10-22 1989-04-26 The Procter & Gamble Company Photoprotection compositions comprising chelating agents
US5683684A (en) * 1991-04-03 1997-11-04 L'oreal Use of sphingolipids in the preparation of a cosmetic or dermopharmaceutical composition protecting the skin and hair against the harmful effects of atmospheric pollution
EP0535446A1 (en) * 1991-09-30 1993-04-07 BONISCONTRO E GAZZONE S.r.l. Pharmaceutical compositions for topical use containing a chelating agent, a tocopheral and an antimicrobial agent
WO1994026263A2 (en) * 1993-05-06 1994-11-24 The Wellcome Foundation Limited Use of a transition metal complex for the treatment of septic shock
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
JPH08333260A (en) * 1995-06-06 1996-12-17 Kaminomoto Honpo:Kk Skin preparation for external use
WO1997015280A1 (en) * 1995-10-26 1997-05-01 L'oreal Use of at least one no synthase inhibitor for treating sensitive skin
JPH10120557A (en) * 1996-10-16 1998-05-12 Sekisui Chem Co Ltd Substance for treating wound
JPH10279485A (en) * 1997-04-01 1998-10-20 Nisshin Oil Mills Ltd:The Composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199709, Derwent World Patents Index; Class B05, AN 1997-095410, XP002198007 *
DATABASE WPI Section Ch Week 199829, Derwent World Patents Index; Class B05, AN 1998-328378, XP002198009 *
DATABASE WPI Section Ch Week 199901, Derwent World Patents Index; Class B02, AN 1999-005165, XP002198008 *
SAUERMANN G ET AL: "Influence of NO-Synthase Antagonists in Rosacea Patients", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 4, no. 108, 1 April 1997 (1997-04-01), pages 657, XP002075670, ISSN: 0022-202X *

Also Published As

Publication number Publication date
WO2002102345A2 (en) 2002-12-27
FR2825920A1 (en) 2002-12-20
FR2825920B1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
EP2311488A3 (en) Vaccine composition
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
HUP0600141A3 (en) Low hygroscopic aripiprazole-anhydrate process for its preparation, pharmaceutical compositions containing it and its use
WO2002022559A3 (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2004005472A3 (en) Inhibitors of ftsz and uses thereof
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
WO2002102345A3 (en) Deferoxamine as an no synthase inhibitor and uses thereof
EP1685845A4 (en) Sialogogue and, containing the same, oral composition and food composition
AU2002231219A1 (en) Water soluble, randomly substituted partial n-, partial o-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
EP1550448A4 (en) Histamine release inhibitor
MXPA03003314A (en) C-nitrosoaniline compounds and their blends as polymerization inhibitors.
WO2003000186A3 (en) Novel phenylamino-pyrimidines and uses thereof
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
MXPA03002207A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors.
WO2002100442A3 (en) Use of l-polynucleotides and derivatives thereof for in vivo imaging
AU2001275677A1 (en) 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants
WO2002050067A3 (en) Pharmaceutical heterocyclic compounds
AU2002231961A1 (en) Detectable compositions, methods of forming the same and detection techniques
HUP0400438A3 (en) Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
WO2002062304A3 (en) Cosmetic and/or pharmaceutical agents containing an acylated amino acid and a protein condensate
AU2002248432A1 (en) Oxazole derivatives, their preparation and their use as cytokine inhibitors
AU2002361337A1 (en) Amphoteric polysaccharide, composition and use
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
HUP0204554A3 (en) Endoparasiticidal composition, preparation and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP